Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Breast Cancer 1

Interventions

Temozolomide 59 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 16 Carboplatin 10 Specimen Handling 9 Carmustine 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 palbociclib 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡